本帖最后由 老马 于 2012-1-13 21:20 编辑 / D7 v6 |% h5 H+ A# D5 J
2 Q! T. b& O1 A. ~" R9 C) a
爱必妥和阿瓦斯丁的比较+ H3 t$ O+ z8 ?9 n" x* u
/ J, g# j+ F$ }1 v
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 n# | b4 a# K/ o% N$ o
9 a" ?" e, D* q
) b( c. y. } S4 A& T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 h$ j. p9 A$ y( u% k, p7 ?8 W4 _5 B==================================================; _& z" Q% n/ D c; O
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
^4 l$ {5 v# U3 Y/ G) aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& B: k: ^* z5 c+ ?Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 j6 m" V9 A% F. r7 n
|